IP
VNRX icon

Intellectus Partners’s VolitionRx Ltd VNRX Stock Holding History

Intellectus Partners’s Portfolio VNRX Stock Details VNRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-14
Closed -$1K – 808
2017
Q2 		$1K Hold
14
– – ﹤0.01% 749
2017
Q1 		$1K Hold
14
– – ﹤0.01% 678
2016
Q4 		$1K Buy
+14
New +$1.26K ﹤0.01% 668

Other funds holding VNRX

LIM
Lagoda Investment Management New York $182M AUM 58.16% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.4B AUM 49.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LCM
Leisure Capital Management Costa Mesa, California $320M AUM 39.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
GBA
Garrison Bradford & Associates New York $92.2M AUM 19.08% 1-Year Est. Return

Intellectus Partners's VNRX Position: Q3 2017 in Review

Intellectus Partners sold out of VolitionRx Ltd (VNRX) in Q3 2017, closing a stake of 14 shares — an estimated $1K sold.

Intellectus Partners first reported a position in VNRX in Q4 2016 and held it in 3 quarters. The position peaked at $1K in Q2 2017. 19 funds tracked by Wall St. Rank hold VNRX as of Q3 2017.

  • Intellectus Partners reported no remaining VolitionRx Ltd position as of Q3 2017 after selling out during the quarter.
  • Intellectus Partners sold 14 VolitionRx Ltd shares in Q3 2017, an estimated $1K.
  • Intellectus Partners first reported a position in VolitionRx Ltd in Q4 2016 and held it in 3 quarters.
  • Intellectus Partners's VolitionRx Ltd position peaked at $1K in Q2 2017.
  • 19 funds tracked by Wall St. Rank held VolitionRx Ltd as of Q3 2017.

Based on Intellectus Partners's 13F filing for Q3 2017, filed 14 Nov 2017.